share_log

6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

6-K:外國發行人報告
美股SEC公告 ·  08/01 16:17
Moomoo AI 已提取核心訊息
On August 1, 2024, Apollomics Inc., a foreign private issuer, filed a Form 6-K with the United States Securities and Exchange Commission, announcing executive changes as part of its strategic focus and cost reduction efforts. The company disclosed that Sanjeev Redkar, Ph.D., co-founder and President, along with Peony Yu, M.D., Chief Medical Officer, have stepped down from their positions. Both executives are transitioning to consulting roles, with Dr. Redkar continuing to serve on the Board of Directors. The announcement was made official by the signature of CEO Guo-Liang Yu.
On August 1, 2024, Apollomics Inc., a foreign private issuer, filed a Form 6-K with the United States Securities and Exchange Commission, announcing executive changes as part of its strategic focus and cost reduction efforts. The company disclosed that Sanjeev Redkar, Ph.D., co-founder and President, along with Peony Yu, M.D., Chief Medical Officer, have stepped down from their positions. Both executives are transitioning to consulting roles, with Dr. Redkar continuing to serve on the Board of Directors. The announcement was made official by the signature of CEO Guo-Liang Yu.
2024年8月1日,外國私營發行人阿波羅米克斯公司向美國證券交易委員會提交了6-k表格,宣佈了管理層變動作爲其戰略重點和成本削減努力的一部分。公司披露,共同創始人兼總裁 Sanjeev Redkar 博士和首席醫療官 Peony Yu 萬博士已辭去他們的職位。這兩位高管正在過渡到諮詢角色,Redkar 博士繼續擔任董事會成員。該公告由 CEO 郭亮宇簽名確認。
2024年8月1日,外國私營發行人阿波羅米克斯公司向美國證券交易委員會提交了6-k表格,宣佈了管理層變動作爲其戰略重點和成本削減努力的一部分。公司披露,共同創始人兼總裁 Sanjeev Redkar 博士和首席醫療官 Peony Yu 萬博士已辭去他們的職位。這兩位高管正在過渡到諮詢角色,Redkar 博士繼續擔任董事會成員。該公告由 CEO 郭亮宇簽名確認。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息